Clostridioides Difficile Treatment Updates

In 2021, the Infectious Disease Society of America and Society for Healthcare Epidemiology of America published focused updates for managing patients with Clostridioides difficile infection (CDI). This presentation will review the updated CDI recommendations and assess the emerging literature surrounding factors influencing the optimal pharmacologic management of initial CDI and recurrent CDI. The presentation will also review considerations for probiotic co-administration as a CDI preventative in patients prescribed antibiotics.

Credits: 1.50 contact hours; 1.50 are pharmacology
Expiration Date: December 31, 2024

$40.00

LEARNING OBJECTIVES

After taking part in this educational activity, participants should be better able to:

-As a result of this activity, the learner will be able to formulate effective evidence-based therapies for Clostridioides difficile infections.

-As a result of this activity, the learner will be able to describe the characteristics of effective extended course therapy for Clostridioides difficile infections.

-As a result of this activity, the learner will be able to list key considerations for using probiotics to prevent Clostridioides difficile infections

CE INFORMATION

Obtain Your Credits

To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned'  for future access.

Designation Statement

NPACE designates this educational activity for a maximum of 1.50 contact hours, of which 1.50 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.

Accreditation Statement

Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.

DISCLOSURES

Faculty

Contributing faculty, Eric Wombwell, PharmD, BCIDP, have disclosed no relevant financial relationships.

Planners

All planners and contributors involved in this educational activity have disclosed no relevant financial relationships. 

Disclaimer

The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.

Disclosure of Unlabeled Use

This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

There is no commercial support for this activity.